Opinion

Video

Atopic dermatitis Clinical Trial Endpoints

Author(s):

Christopher G. Bunick, MD, PhD

An atopic dermatitis expert discusses the primary and secondary efficacy endpoints and treatment goals commonly assessed in clinical trials for moderate to severe atopic dermatitis.

  1. Please share primary and secondary efficacy outcomes/treatment targets routinely examined in atopic dermatitis clinical trials for moderate to severe atopic dermatitis.
  2. Is there consensus amongst experts on treatment targets? 
Related Videos
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
4 experts are featured in this series.
4 experts are featured in this series.
A. Sidney Barritt, MD | Credit: UNC School of Medicine
Related Content
Rohit Loomba, MD | Credit: AASLD
November 21st 2024

Rohit Loomba, MD: Promising Phase 2a HERALD Data for ALG-055009 in MASH

Abigail Brooks, MA
Diabetes Dialogue: News and Updates in Diabetes at AHA 2024
November 21st 2024

Diabetes Dialogue: News and Updates in Diabetes at AHA 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Søren Andrea Just, MD, PhD, associate professor, University of Southern Denmark, and Odense University Hospital – Svendborg.
November 21st 2024

AI Assessments, Robotics Perform to Rheumatologist Levels in Joint Assessment

Victoria Johnson
The Medical Sisterhood: Role Models and Mentorship, with Susan Taylor, MD, and Linda Stein Gold, MD
November 18th 2024

The Medical Sisterhood: Role Models and Mentorship, with Susan Taylor, MD, and Linda Stein Gold, MD

Mona Shahriari, MD, FAAD Linda Stein Gold, MD Susan Taylor, MD
FDA Approves Bimekizumab for Adults with Hidradenitis Suppurativa
November 20th 2024

FDA Approves Bimekizumab for Adults with Hidradenitis Suppurativa

Tim Smith
New Medical Guidance Provides Insurance Recommendations for Allergen Immunotherapy
November 20th 2024

New Medical Guidance Provides Insurance Recommendations for Allergen Immunotherapy

Tim Smith
© 2024 MJH Life Sciences

All rights reserved.